SECTOR:

Anti Infectives

FUND/VEHICLE:

Pivotal US

INVESTMENT DATE:

2017

GEOGRAPHY:

North America

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sciences, Pivotal bioVenture Partners, Sofinnova, TPG Biotechnology Partners and Eventide Gilead Fund, to advance our pipeline of breakthrough anti-infective products.